Jto 2022

2 papers

Top Research Directions

The 5 research directions with Jto 2022 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Evaluating Clinical Outcomes Using Historical Patient Cohorts150.0%
2Overcoming Resistance and Toxicity in Conventional Cancer Therapies150.0%
3Remodeling the Tumor Microenvironment with Combination Immunotherapy150.0%
4Stratifying Patients for Targeted Immunotherapy Response150.0%
5The Non-Additive Toxicity of Multi-Modal Adjunctive Therapies150.0%

Download all directions as CSV

Institutions

Institutions credited by Jto 2022 papers: a paper credits every institution named in its affiliations, once. 11 institutions share 1 credited papers.

#InstitutionPapersShare
100z0j0d77 1100.0%
201f77gp95 1100.0%
3025020z88 1100.0%
402tbvhh96 1100.0%
5033nbnf69 1100.0%
6043ek5g31 1100.0%
704py1g812 1100.0%
8055gkcy74 1100.0%
9Huazhong University of Science and Technology 1100.0%
10Tongji University 1100.0%
11Zhejiang University 1100.0%

Download all institutions as CSV

About this data

Papers. Jto 2022 lists 2 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 2 papers (50.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Jto 2022”, https://lacuna.tiptreesystems.com/venue/jto/2022.

Top Authors

AuthorPapers
Jianhua Chen2

Papers

Title
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors